Dapagliflozin corrects hypomagnesemia in kidney-transplant patients
Journal of Nephrology · 2026
DOI: 10.1093/joneph/aajag046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Douchka Guillot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research in Transplantation and Translational Immunology, Nantes Université, CHU Nantes, INSERM, UMR 1064, ITUN, Nantes, France. Hauptthemen laut MEDLINE: Kidney Transplantation, Benzhydryl Compounds, Magnesium, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Hypomagnesemia frequently occurs after kidney transplantation, potentially contributing to morbidity. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, have proven benefits in chronic kidney disease, but their effects on serum magnesium in non-diabetic transplant recipients remain unclear.
Methods
We retrospectively studied 122 adult kidney-transplant recipients who initiated dapagliflozin between September 2020 and July 2023. We obtained two serum samples: one before and one after dapagliflozin initiation in 94 patients. After excluding patients with inadequate sampling or early discontinuation, 34 patients were analyzed and compared with 96 controls not receiving dapagliflozin.
Results
At baseline, hypomagnesemia was present in 26.5% of dapagliflozin-treated patients and 22.9% of controls. After a median of 8.1 months on dapagliflozin, serum magnesium increased significantly (P = .00018), correcting hypomagnesemia in 7 of 9 affected patients. No significant change occurred in the control group. Serum phosphate also significantly increased (P = .026), while estimated glomerular filtration rate (eGFR) declined (P = .0001), consistent with known hemodynamic effects of SGLT2i. No significant variations in magnesium, phosphate, or eGFR were observed among controls.
Conclusions
In this cohort, dapagliflozin use was associated with improved serum magnesium in kidney-transplant recipients, particularly those with baseline hypomagnesemia, thus warranting further prospective investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research in Transplantation and Translational Immunology, Nantes Université, CHU Nantes, INSERM, UMR 1064, ITUN, Nantes, France.
- Biochemestry Laboratory, Nantes University Hospitals, Nantes, France.
- Histocompatibility Laboratory, Etablissement Français du Sang, Nantes, France.
- Centers for Rare Diseases Filière OSCAR and Filière ORKID, Nantes University Hospital, Nantes, France.
- Division of Intensive Care Medicine, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
- Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
ORCID-Profile: Douchka Guillot, Lucile Figueres
Zitieren
APA
Guillot, D., Dejoie, T., Kerleau, C., Walencik, A., Dantal, J., Maillard, C., Legouis, D., & Figueres, L. (2026). Dapagliflozin corrects hypomagnesemia in kidney-transplant patients. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag046
Vancouver
Guillot D, Dejoie T, Kerleau C, Walencik A, Dantal J, Maillard C, et al. Dapagliflozin corrects hypomagnesemia in kidney-transplant patients. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag046
BibTeX
@article{Guillot2026,
author = {Guillot, Douchka and Dejoie, Thomas and Kerleau, Clarisse and Walencik, Alexandre and Dantal, Jacques and Maillard, Clémence and Legouis, David and Figueres, Lucile},
title = {Dapagliflozin corrects hypomagnesemia in kidney-transplant patients},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajag046}
}
EUVIMED